Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________________________________ FORM 10-Q _______________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Com ...

Nektar Therapeutics (NASDAQ:NKTR) Q4 2019 Results Conference Call February 27, 2020 5:00 PM ET CompanyParticipants Jennifer Ruddock - Senior Vice President, Strategy and Corporate Affairs Howard Robin - President and Chief Executive Officer Dr. Wei Lin - Senior Vice President and Head of Development Dr. Jonathan Zalevsky - Chief Research and Development Officer Gil Labrucherie - Chief Operating Officer and Chief Financial Officer Conference Call Participants Chris Shibutani - Cowen Alexander Duncan - Piper ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ___________________________________________________________________________ Form 10-K ___________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to ...

NEKTAR® 38th Annual J.P. Morgan Healthcare Conference Howard Robin President & CEO January 13, 2020 2 This presentation includes forward-looking statements regarding Nektar's proprietary drug candidates, the timing of the start and conclusion of ongoing or planned clinical trials, the timing and outcome of regulatory decisions, and future availability of clinical trial data. Actual results could differ materially and these statements are subject to important risks detailed in Nektar's filings with the SEC i ...

NEKTAR® SMARTER MEDICINE™ Jefferies 2019 London Healthcare Conference Jonathan Zalevsky, PhD Chief R&D Officer November 20, 2019 2 This presentation includes forward-looking statements regarding Nektar's proprietary drug candidates, the timing of the start and conclusion of ongoing or planned clinical trials, the timing and outcome of regulatory decisions, and future availability of clinical trial data. Actual results could differ materially and these statements are subject to important risks detailed in Ne ...

NEKTAR® NEW PATHWAYS TO SMARTER MEDICINE™ SITC 2019 Nektar Therapeutics Investor & Analyst Call November 10, 2019 This presentation includes forward-looking statements regarding Nektar's proprietary drug candidates, the timing of the start and conclusion of ongoing or planned clinical trials, the timing and outcome of regulatory decisions, and future availability of clinical trial data. Actual results could differ materially and these statements are subject to important risks detailed in Nektar's filings wi ...

Nektar Therapeutics (NASDAQ:NKTR) Q3 2019 Earnings Conference Call November 6, 2019 5:00 PM ET Company Participants Jennifer Ruddock - Head of Investor Relations Howard Robin - President & Chief Executive Officer Gil Labrucherie - Chief Operating Officer & Chief Financial Officer Jonathan Zalevsky - Head of Research & Development Conference Call Participants Chris Shibutani - Cowen Jessica Fye - JPMorgan Tyler Van Buren - Piper Jaffray Alex Lim - Mizuho George Farmer - BMO Capital Markets Gobind Singh - BMO ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________________________________ FORM 10-Q _______________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ...

Nektar Therapeutics (NASDAQ:NKTR) Q2 2019 Earnings Conference Call August 8, 2019 5:00 PM ET Company Participants Jennifer Ruddock ??? Head of Investor Relations Howard Robin ??? President and CEO Gil Labrucherie ??? Chief Financial Officer Stephen Doberstein ??? Head of R&D Jonathan Zalevsky ??? Chief Scientific Officer Mary Tagliaferri ??? Chief Medical officer Conference Call Participants Chris Shibutani ??? Cowen Jessica Fye ??? JPMorgan Tyler Van Buren ??? Piper Jaffray Paul Choi ??? Goldman Sachs Alex ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________________________________ FORM 10-Q _______________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm ...